Eloralintide vs Cagrilintide at a Glance
The two drugs belong to the same class but differ in who makes them, which receptors they target and how far along they are. This table sums up what has been published as of October 28, 2026.
At a Glance
| Detail | Eloralintide | Cagrilintide |
|---|---|---|
| Developer | Eli Lilly | Novo Nordisk |
| Receptors targeted | Amylin receptors (selective) | Amylin and calcitonin receptors (non-selective) |
| How it is given in trials | Once-weekly injection | Once-weekly injection |
| Best standalone weight loss reported | Up to 20.1% at 48 weeks (Phase 2) | 11.8% at 68 weeks (Phase 3 sub-analysis) |
| Combination in development | EloraTZP (with tirzepatide) | CagriSema (with semaglutide) |
| Status | Phase 3 trials ongoing; not approved | CagriSema under FDA review; not approved |
If you are new to this drug class, our guide to what an amylin receptor agonist is explains how amylin works in plain English.
How Eloralintide and Cagrilintide Work Differently
Both drugs work mainly by helping you feel full sooner, so you eat less. The main difference is which receptors they switch on. Lilly’s discovery paper on eloralintide describes eloralintide as selective for amylin receptors and cagrilintide as non-selective, meaning it also activates calcitonin receptors, close relatives of the amylin receptor.
Lilly designed eloralintide this way on purpose. When it announced its Phase 2 results, the company said it believes molecule specificity is important in this class. In rat studies described in the same discovery paper, eloralintide caused less nausea-like behavior than cagrilintide.
That animal finding is interesting, but it is not proof that people will feel the same difference. No published trial has given eloralintide and cagrilintide to people side by side.
Weight Loss Results: What the Trials Show
In separate trials, eloralintide alone produced more average weight loss than cagrilintide alone, but these results come from different studies and cannot be ranked directly. Here is what each trial reported for people who stayed on treatment.
Trial Results Side by Side
| Trial | People enrolled | Length | Average weight loss vs placebo |
|---|---|---|---|
| Eloralintide Phase 2 | 263 adults without type 2 diabetes | 48 weeks | 9.5% to 20.1%, depending on dose, vs 0.4% |
| Cagrilintide Phase 2 | 706 adults without diabetes (all dose groups) | 26 weeks | 6.0% to 10.8%, depending on dose, vs 3.0% |
| Cagrilintide alone in REDEFINE 1 (Phase 3) | Adults with obesity or overweight, without diabetes | 68 weeks | 11.8% vs 2.3% |
The eloralintide figures come from Lilly’s Phase 2 eloralintide results. The cagrilintide figures come from the Lancet report on the cagrilintide Phase 2 trial and Novo Nordisk’s REDEFINE 1 results for cagrilintide alone.
Why not call eloralintide the winner? A few reasons:
- Different trial lengths. Weight loss usually keeps building for months, so a 26-week result and a 48-week result are not on the same footing.
- Different doses. Eloralintide’s top result came from its 9 mg dose. Cagrilintide’s Phase 3 data used a 2.4 mg dose, and its higher 4.5 mg dose was only tested for 26 weeks.
- Different trial stages. Eloralintide’s numbers come from a 263-person Phase 2 trial. Cagrilintide has Phase 3 data from a much larger program.
In the cagrilintide Phase 2 trial, its 4.5 mg dose also beat liraglutide 3.0 mg, an older GLP-1 weight loss drug, by 10.8% to 9.0% at 26 weeks, according to the Lancet trial report.
The doses in this section come from research studies and are listed for information only. Neither eloralintide nor cagrilintide has an approved dose. Talk to your prescriber about any weight loss medicine before starting or changing treatment.
Side Effects and Tolerability Compared
Both drugs mainly cause stomach-related side effects, such as nausea, and these were mostly mild to moderate in trials. Eloralintide also caused fatigue more often than placebo at higher doses.
Side Effects Side by Side
| Detail | Eloralintide (Phase 2, 48 weeks) | Cagrilintide |
|---|---|---|
| Most common side effects | Nausea and fatigue | Nausea, vomiting, diarrhea and constipation |
| Nausea rates | 11% to 64% across dose groups vs 14% on placebo | 20% to 47% across dose groups vs 18% on placebo (Phase 2, 26 weeks) |
| Stopping due to nausea | Not broken out in the Lilly release | 1.0% vs 0.1% on placebo (REDEFINE 1) |
| What helped | Raising the dose slowly lowered side effects | Side effects were mostly temporary |
The eloralintide side effect rates were published in the Lancet report on the 48-week eloralintide trial. The cagrilintide rates come from its 26-week Phase 2 trial in The Lancet and Novo Nordisk’s REDEFINE 1 cagrilintide results.
The nausea ranges are wide because both trials tested many doses and dosing schedules. For eloralintide, Lilly reported that side effects at the 1 mg and 3 mg doses were similar to placebo. Our post on eloralintide side effects goes through each dose in more detail.
CagriSema vs EloraTZP: The Combination Race
Both companies are pairing their amylin drug with an approved weight loss medicine, and Novo’s combination is further ahead. CagriSema combines cagrilintide with semaglutide, the medicine in Wegovy. EloraTZP combines eloralintide with tirzepatide, the medicine in Zepbound and Mounjaro.
CagriSema vs EloraTZP
| Detail | CagriSema | EloraTZP |
|---|---|---|
| Ingredients | Cagrilintide plus semaglutide | Eloralintide plus tirzepatide |
| Key trial | REDEFINE 1 (Phase 3), 3,417 adults without diabetes, 68 weeks | Phase 2b, 367 adults with obesity or overweight and type 2 diabetes, 48 weeks |
| Reported weight loss | 20.4% vs 3.0% on placebo | Up to 23.3%, more than tirzepatide 15 mg alone |
| Status (October 2026) | Under FDA review; decision expected Q4 2026 | Lilly plans to start Phase 3 in Q4 2026 |
CagriSema’s results were published in the New England Journal of Medicine REDEFINE 1 trial report, and its FDA timeline comes from Novo Nordisk’s September 2026 CagriSema update. The EloraTZP figures come from Lilly’s EloraTZP Phase 2b results announcement.
These trials enrolled different groups. People with type 2 diabetes usually lose less weight on these medicines than people without diabetes, so EloraTZP’s result and CagriSema’s result are not directly comparable either. Our roundup of new weight loss drugs covers CagriSema and other medicines in development.
What About Petrelintide and Other Amylin Drugs?
Petrelintide is a third once-weekly amylin drug, developed by Zealand Pharma and Roche, and it is also still investigational. In its Phase 2 ZUPREME-1 trial, people lost up to 10.7% of their body weight at 42 weeks compared with 1.7% on placebo, according to Roche’s Phase 2 announcement. Zealand said in September 2026 that its Phase 3 program has started.
Retatrutide also comes up in these discussions, but it is not an amylin drug. Lilly describes it as an investigational triple receptor agonist that acts on GIP, GLP-1 and glucagon receptors. It is not approved and not for sale. You can learn more in our posts on what retatrutide is and retatrutide vs tirzepatide.
Which One Is Closer to Being Available?
Cagrilintide is closer, mainly because of CagriSema. Novo Nordisk filed CagriSema with the FDA in December 2025 and expects a decision in the fourth quarter of 2026. Novo also said it would start a dedicated Phase 3 program for cagrilintide on its own, called RENEW.
Eloralintide is in Phase 3 trials, and Lilly has not announced an FDA filing. Until regulators approve either drug, the only legitimate way to get one is by joining a clinical trial.
Eloralintide and cagrilintide are not approved medicines. Vials sold online under these names, often labeled “for research use only,” are not FDA-approved drugs, and there is no way to confirm what is in them or how pure they are. Do not inject any product that is not prescribed to you and dispensed by a licensed pharmacy. Our guide on how to spot counterfeit medicines explains the warning signs.
Approved Options You Can Use Now
If you want weight loss treatment now, approved medicines that work through related pathways are available with a prescription. Wegovy (semaglutide) and Zepbound (tirzepatide) are the same medicines that Novo and Lilly are pairing with their amylin drugs. Our Zepbound vs Wegovy comparison explains how they differ.
You can order Wegovy through Pharma Giant, which fills U.S. prescriptions with licensed Canadian pharmacies. Zepbound is also available with a valid prescription.
Whichever medicine you use, get it from a licensed pharmacy, take it exactly as prescribed, and talk with your prescriber before starting, stopping or switching treatment.
Order Wegovy Through Pharma Giant
We fill U.S. prescriptions with licensed Canadian pharmacies. A valid prescription is required.




